Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know [Seeking Alpha]
Corvus Pharmaceuticals, Inc. (CRVS)
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corvuspharma.com
Company Research
Source: Seeking Alpha
Soquelitinib achieved 75% EASI-75 and 33% IGA 0/1 rates, with favorable safety and biomarker evidence supporting its differentiated immunomodulatory mechanism. CRVS initiated a $150M equity offering to extend cash runway and fund pivotal Phase 2/3 trials, with durability of response as the next critical catalyst. Valuation is driven by soquelitinib's potential in a $17B–$30B atopic dermatitis market, but high risk remains given pre-revenue status and clinical development uncertainties. Love Employee/iStock via Getty Images Thesis: Positive Soquelitinib Data Signals More Upside Corvus Pharmaceuticals, Inc. ( CRVS ) lead asset would have to be soquelitinib. It's an investigational oral small-molecule drug being developed by Corvus. It's been seen to selectively inhibit interleukin-2–inducible This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such posit
Show less
Read more
Impact Snapshot
Event Time:
CRVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRVS alerts
High impacting Corvus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRVS
News
- Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $30.00 price target on by analysts at Mizuho.MarketBeat
- Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals (CRVS) Soars 212% on Impressive Eczema Therapy Study [Yahoo! Finance]Yahoo! Finance
- Why Corvus Pharmaceuticals (CRVS) Is Up 211.8% After Upsized Equity Raise On Soquelitinib Phase 2 Plans [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201MGlobeNewswire
CRVS
Earnings
- 11/4/25 - Beat
CRVS
Sec Filings
- 2/5/26 - Form SCHEDULE
- 1/30/26 - Form 4
- 1/30/26 - Form SCHEDULE
- CRVS's page on the SEC website